MAPK3 and Huntington disease: In contrast, HD (healthy donor) PBMC were relatively resistant to Erk1/2i (0–15 μM for 72 h) and CDK4/6i (0–2.5 μM for >96 h), suggesting a favorable therapeutic index (Fig. 1B4,B8, Fig. S2).